Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area.
about
Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinomaThe impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy.The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 casesThe Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.Prognostic value of metabolic tumor volume as measured by fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in nasopharyngeal carcinoma.Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: A meta-analysis.Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma.Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial.Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases.Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma.Accuracy of a Staging System for Prognosis of 5-Year Survival of Patients With Nasopharyngeal Carcinoma Who Underwent Chemoradiotherapy.
P2860
Q35087399-C42AA8DB-AACC-4806-8C6D-3059D9A81C94Q35870838-241B8179-D0E0-41E8-AB2C-AC8CCD81D52FQ36152889-A71AD9E7-5538-4617-A6F3-0D0F36AB2038Q36793052-17DC91B0-6F11-47EC-9E95-025A8EA1E82BQ38249891-7DDF7A2E-8C7E-41E1-AF4F-09F288D9EE6FQ38982843-693686AF-E308-45B7-B21F-F6C99B199EAFQ40333888-BF1C13B5-36D7-4419-BFE3-6CAC084F1BF1Q40458882-DDBE6B76-28B5-4D80-BB81-E8D1D1F47BE7Q40633739-6139AC58-6099-4C45-8AC4-C22C9ED0E7B3Q41721746-2CF8C471-7ADD-44BF-BE4B-40A33B7DE32FQ41757247-00848F76-A465-4E4C-995D-28DC4D01C70FQ47870613-FD34062A-73C3-4F49-B999-825291C05442
P2860
Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Pretreatment Epstein-Barr viru ...... institute in an endemic area.
@en
Pretreatment Epstein-Barr viru ...... institute in an endemic area.
@nl
type
label
Pretreatment Epstein-Barr viru ...... institute in an endemic area.
@en
Pretreatment Epstein-Barr viru ...... institute in an endemic area.
@nl
prefLabel
Pretreatment Epstein-Barr viru ...... institute in an endemic area.
@en
Pretreatment Epstein-Barr viru ...... institute in an endemic area.
@nl
P2093
P356
P1476
Pretreatment Epstein-Barr viru ...... institute in an endemic area.
@en
P2093
Guoyi Zhang
Hemei Chen
Weihong Wei
Zeli Huang
P356
10.1159/000360178
P577
2014-02-21T00:00:00Z